Equities Analysts Offer Predictions for ENTA Q1 Earnings

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Enanta Pharmaceuticals in a research report issued to clients and investors on Tuesday, December 24th. HC Wainwright analyst E. Arce forecasts that the biotechnology company will earn ($1.18) per share for the quarter. HC Wainwright has a "Buy" rating and a $18.00 price target on the stock. The consensus estimate for Enanta Pharmaceuticals' current full-year earnings is ($4.73) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals' Q2 2025 earnings at ($1.32) EPS, Q3 2025 earnings at ($1.45) EPS, Q4 2025 earnings at ($1.58) EPS, FY2025 earnings at ($5.54) EPS, FY2026 earnings at ($7.90) EPS, FY2027 earnings at ($8.00) EPS and FY2028 earnings at ($7.36) EPS.

Other analysts also recently issued reports about the company. Robert W. Baird cut their price objective on Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating for the company in a research report on Tuesday, November 26th. JMP Securities reaffirmed a "market outperform" rating and set a $21.00 price objective (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $17.25.

Enanta Pharmaceuticals Price Performance

ENTA traded up $0.01 during trading hours on Friday, reaching $6.01. The company's stock had a trading volume of 328,292 shares, compared to its average volume of 226,296. Enanta Pharmaceuticals has a fifty-two week low of $5.70 and a fifty-two week high of $17.80. The stock has a market cap of $127.38 million, a PE ratio of -1.10 and a beta of 0.49. The business's 50-day moving average is $9.28 and its 200-day moving average is $11.53.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last issued its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.16) by ($0.20). The company had revenue of $14.60 million during the quarter, compared to analyst estimates of $17.99 million. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The firm's revenue was down 22.8% compared to the same quarter last year. During the same period last year, the business earned ($1.33) earnings per share.

Insider Activity at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly sold 5,142 shares of the business's stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the completion of the sale, the chief executive officer now owns 801,638 shares in the company, valued at $6,461,202.28. The trade was a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 13.64% of the stock is currently owned by corporate insiders.

Institutional Trading of Enanta Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC purchased a new position in shares of Enanta Pharmaceuticals in the 2nd quarter valued at $35,000. US Bancorp DE grew its holdings in shares of Enanta Pharmaceuticals by 4,933.7% during the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 4,243 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Enanta Pharmaceuticals during the third quarter worth about $122,000. Quest Partners LLC boosted its position in shares of Enanta Pharmaceuticals by 511.2% in the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $150,000 after purchasing an additional 9,692 shares during the period. Finally, Valence8 US LP acquired a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter valued at about $207,000. Institutional investors and hedge funds own 94.99% of the company's stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.